Germany
CatalYm GmbH, founded in 2016, is a Germany-based company deeply embedded in the Biotechnology and Health Care sectors. The company's mission—"Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems"—captures its commitment to advancing medical treatments through revolutionary approaches.
CatalYm focuses on the development of antibodies that target a placental factor, which is often overproduced in various tumors. This innovative approach positions CatalYm as a leader in creating immunotherapies with the potential to dramatically improve outcomes for cancer patients globally.
Recently, the company secured a substantial $150.00M Series D investment on 16 July 2024. The financing round saw participation from notable investors including Canaan Partners, Forbion, Gilde Healthcare, Novartis, Bioqube Ventures, Jeito Capital, Omega Funds, Vesalius Biocapital, and Brandon Capital, underscoring the strong confidence in CatalYm's innovative platform and market potential.
Navio